Two studies showed that, in animal models of asthma and other AIDs, an IL-2–NAEi protein drug conjugate that inhibits cullin5 neddylation showed significantly better efficacy than just using low-dose IL-2 in suppressing the progression of autoimmunity and asthma [124,126]. The gene discussed is IL2; the disease is asthma.